Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹13 Cr
Revenue (TTM)
₹9 Cr
Net Profit (TTM)
₹-1 Cr
ROE
0 %
ROCE
-10.1 %
P/E Ratio
--
P/B Ratio
-0.9
Industry P/E
26.59
EV/EBITDA
70
Div. Yield
0 %
Debt to Equity
-1.5
Book Value
₹-15.1
EPS
₹-0.6
Face value
10
Shares outstanding
10,000,700
CFO
₹-1.63 Cr
EBITDA
₹-5.27 Cr
Net Profit
₹-20.16 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Norris Medicines
| -15.7 | -11.8 | -15.5 | -21.8 | 8.7 | 15.5 | -- |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Norris Medicines
| -6.2 | 26.0 | -1.9 | 29.7 | 71.3 | 59.0 | -19.5 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Norris Medicines
|
13.4 | 13.4 | 9.5 | -0.6 | -0.8 | -- | -- | -0.9 |
| 2,791.2 | 34,920.1 | 5,201.6 | 1,014.6 | 22.9 | 25 | 34.4 | 7.6 | |
| 7,827.5 | 19,544.3 | 2,177.5 | 200.9 | 11.3 | 26.5 | 97.3 | 23.5 | |
| 1,565.8 | 11,917.5 | 2,089.5 | 622.0 | 31.3 | 20.4 | 19.4 | 3.6 | |
| 1,332.1 | 18,429.0 | 3,078.2 | 469.4 | 26.4 | 14.9 | 42.7 | 5.1 | |
| 1,961.1 | 31,410.1 | 4,193.0 | 753.8 | 22.7 | 20.8 | 41.7 | 7.8 | |
| 4,887.1 | 22,333.8 | 2,482.3 | 853.6 | 33.7 | 18.9 | 26.2 | 5.6 | |
| 4,778.6 | 7,918.9 | 1,348.5 | 293.5 | 28.1 | 50.7 | 27 | 11.4 | |
| 388.9 | 7,603.2 | 1,432.0 | 149.0 | 19.1 | 7.9 | 50.7 | 3.1 | |
| 971.2 | 8,938.5 | 4,725.6 | 528.7 | 14.9 | 20.7 | 17.5 | 3.0 |
No Review & Analysis are available.
Manufacture of pharmaceuticals, medicinal chemical and botanical products
Incorporated
1990
Chairman
--
Managing Director
--
Headquarters
Ankleshwar, Gujarat
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Norris Medicines Ltd is ₹13.44 (BSE) as of 02-Apr-2026 IST. Norris Medicines Ltd has given a return of 8.75% in the last 3 years.
Since, TTM earnings of Norris Medicines Ltd is negative, P/E ratio is not available.
The P/B ratio of Norris Medicines Ltd is -0.89 times as on 02-Apr-2026, a 120 discount to its peers’ median range of 4.49 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
-1.12
|
|
2024
|
0.00
|
-0.99
|
|
2023
|
0.00
|
-0.83
|
|
2022
|
0.00
|
0.00
|
|
2021
|
0.00
|
-0.87
|
The 52-week high and low of Norris Medicines Ltd are Rs 22.10 and Rs 12.00 as of 05-Apr-2026.
Norris Medicines Ltd has a market capitalisation of ₹ 13 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Norris Medicines Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹0.19
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.